Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 16.00 is 56% above its 5-year average of 10.25, around the middle of its 5-year range (1.02–45.15).
As of the fiscal period ended Tuesday, June 30, 2026. 3.77% below its 12-month average of 16.63.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.00.
CURRENT RATIO
16.00
CURRENT RATIO AVG TTM
16.63
CURRENT RATIO AVG 3Y
9.20
CURRENT RATIO AVG 5Y
10.25
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-3.77%
CURRENT VS 3Y AVG
+73.92%
CURRENT VS 5Y AVG
+56.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+326.64%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$258.80M
Current Ratio
16.00
TTM Avg
16.63
3Y Avg
9.20
5Y Avg
10.25
Market Cap
$258.85M
Current Ratio
11.30
TTM Avg
6.79
3Y Avg
6.17
5Y Avg
6.32
Market Cap
$256.77M
Current Ratio
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
Market Cap
$256.68M
Current Ratio
4.48
TTM Avg
4.80
3Y Avg
5.23
5Y Avg
5.23
Market Cap
$261.17M
Current Ratio
4.50
TTM Avg
8.35
3Y Avg
6.79
5Y Avg
6.91
Market Cap
$261.28M
Current Ratio
8.88
TTM Avg
8.27
3Y Avg
7.75
5Y Avg
6.94
Market Cap
$263.41M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $258.80M | 16.00 | 16.63 | 9.20 | 10.25 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $258.85M | 11.30 | 6.79 | 6.17 | 6.32 |
| AC Immune S.A. (ACIU)vs › | $257.37M | 0.93 | 1.36 | 5.78 | 8.29 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $256.77M | 13.89 | 8.37 | 7.38 | 15.00 |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.68M | 4.48 | 4.80 | 5.23 | 5.23 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.17M | 4.50 | 8.35 | 6.79 | 6.91 |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | 24.26 | 16.09 | 10.56 | 7.83 |
| OraSure Technologies, Inc. (OSUR)vs › | $261.28M | 8.88 | 8.27 | 7.75 | 6.94 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | 15.82 | 24.04 | 14.70 | 12.06 |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
Current Ratio
16.00
Quick Ratio
16.00
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 16.00 |
| 2026-03-31 | 19.30 |
| 2025-12-31 | 15.12 |
| 2025-09-30 | 23.98 |
| 2025-06-30 | 8.72 |
| 2025-03-31 | 13.00 |
| 2024-12-31 | 11.10 |
| 2024-09-30 | 4.17 |
| 2024-06-30 | 2.11 |
| 2024-03-31 | 1.95 |
| 2023-12-31 | 1.02 |
| 2023-09-30 | 1.75 |
| 2023-06-30 | 1.35 |
| 2023-03-31 | 8.82 |
| 2022-12-31 | 6.08 |
| 2022-09-30 | 13.66 |
| 2022-06-30 | 10.13 |
| 2022-03-31 | 21.10 |
| 2021-12-31 | 13.49 |
| 2021-09-30 | 12.03 |
| 2021-06-30 | 45.15 |
| 2021-03-31 | 4.21 |
| 2020-12-31 | 0.05 |
| 2020-09-30 | 0.03 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.13 |
| 2019-09-30 | 0.00 |
